로딩 중…
지수 로딩 중…
SELLAS Life Sciences Group, Inc.
SLS· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$11.22+12.09%
2026-08-03
Financials
Valuation Metrics
SELLAS Life Sciences Group, Inc.'s Market Cap is $2.09B. At end of 2025 it was $577M. Ranked #2023 of 3,112 in US market (top 65%), #768 of 1,445 on NASDAQ (top 53%), #130 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 48%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.09B | US#2,023/3,112 Sec#130/269 |
| Revenue | $0.00 | US#2,974/3,112 Sec#204/269 |
| Net Income | $-29M | US—/3,112 Sec—/269 |
| Total Assets | $114M | US#3,030/3,112 Sec#263/269 |
| Net Assets | $107M | US#2,873/3,112 Sec#227/269 |
| Value | ||
| P/B | 19.43x | US#2,805/3,112 Sec#232/269 |
| FCF Yield | -1.35% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -27.42% | US#2,594/3,112 Sec#121/269 |
| ROA | -25.80% | US#2,833/3,112 Sec#146/269 |
| Financial Health | ||
| Debt Ratio | 6.30% | US#62/3,112 Sec#28/269 |
| Total Debt | $871000.00 | US#2,934/3,112 Sec#246/269 |
| FCF | $-28M | US#2,399/3,112 Sec#99/269 |
| Cash | $107M | US#2,177/3,112 Sec#174/269 |
| Current Ratio | 17.22x | US#145/3,112 Sec#43/269 |
| Performance | ||
| 1Y Return | 575.90% | US#7/3,112 Sec#3/269 |
| 1M Return | -25.10% | US#3,019/3,112 Sec#245/269 |
| From 52W High | -29.35% | US#2,145/3,112 Sec#160/269 |
| 1Y MDD | -36.53% | US#1,780/3,112 Sec#125/269 |
| Trading | ||
| Volume | 6,862,750 shares | US#269/3,112 Sec#20/269 |
| Trading Value | $74M | US#1,092/3,112 Sec#67/269 |
| Per Share | ||
| EPS | $-0.18 | US—/3,112 Sec—/269 |
| BPS | $0.46 | US#2,686/3,112 Sec#221/269 |